$20.31
1.10% yesterday
Nasdaq, Dec 20, 10:00 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$20.31
-0.14 0.68% 1M
-5.57 21.52% 6M
-11.53 36.21% YTD
-10.25 33.54% 1Y
-18.52 47.70% 3Y
-1.39 6.41% 5Y
+14.31 238.61% 10Y
Nasdaq, Closing price Fri, Dec 20 2024
+0.22 1.10%
ISIN
US3723032062
Symbol
GMAB
Sector

Key metrics

Market capitalization $12.90b
Enterprise Value $10.46b
P/E (TTM) P/E ratio 19.42
EV/FCF (TTM) EV/FCF 11.10
EV/Sales (TTM) EV/Sales 3.64
P/S ratio (TTM) P/S ratio 4.49
P/B ratio (TTM) P/B ratio 2.70
Revenue growth (TTM) Revenue growth 18.04%
Revenue (TTM) Revenue $2.87b
EBIT (operating result TTM) EBIT $931.50m
Free Cash Flow (TTM) Free Cash Flow $942.23m
Cash position $2.59b
EPS (TTM) EPS $1.05
P/E forward 16.63
P/S forward 4.25
EV/Sales forward 3.45
Short interest 0.32%
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Genmab - ADR forecast:

18x Buy
62%
10x Hold
34%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Genmab - ADR forecast:

Buy
62%
Hold
34%
Sell
3%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,873 2,873
18% 18%
100%
- Direct Costs 113 113
-
4%
2,760 2,760
-
96%
- Selling and Administrative Expenses 516 516
10% 10%
18%
- Research and Development Expense 1,313 1,313
25% 25%
46%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 932 932
4% 4%
32%
Net Profit 675 675
9% 9%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
GlobeNewsWire
10 days ago
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast.
Neutral
Business Wire
12 days ago
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab...
Neutral
Business Wire
13 days ago
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable respon...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,204
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today